Cargando…

Alogliptin benzoate for management of type 2 diabetes

Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saisho, Yoshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401208/ https://www.ncbi.nlm.nih.gov/pubmed/25914541 http://dx.doi.org/10.2147/VHRM.S68564

Ejemplares similares

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets
por: Naseef, Hani, et al.
Publicado: (2018)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes
por: Saisho, Yoshifumi
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
por: Saisho, Yoshifumi
Publicado: (2014)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV
por: Hammad, Sherin F., et al.
Publicado: (2021)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
por: Wang, Hongyu, et al.
Publicado: (2015)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
por: Inaishi, Jun, et al.
Publicado: (2020)

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
por: Saisho, Yoshifumi
Publicado: (2019)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes
por: Saisho, Yoshifumi
Publicado: (2018)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Correction: Sugiyama, K.; et al. Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases 2018, 6, 44
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
por: Mizushige, Tomoko, et al.
Publicado: (2015)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
por: Liu, Xu, et al.
Publicado: (2021)

Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
por: Saisho, Yoshifumi
Publicado: (2014)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

Revisiting Regulators of Human β-cell Mass to Achieve β-cell–centric Approach Toward Type 2 Diabetes
por: Sasaki, Hironobu, et al.
Publicado: (2021)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
por: Berhan, Asres, et al.
Publicado: (2013)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Immunohistochemical Localization of Alogliptin, a DPP-4 Inhibitor, in Tissues of Normal and Type 2 Diabetes Model Rat
por: Yamamoto, Yutaro, et al.
Publicado: (2022)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pvmf3etskpo2ma3957nkrlk71i